ID   M238 R1
AC   CVCL_EI91
DR   cancercelllines; CVCL_EI91
DR   Cosmic; 1545616
DR   Wikidata; Q54903551
RX   PubMed=21107323;
CC   Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D751 ! M238
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 05-10-23; Version: 10
//
RX   PubMed=21107323; DOI=10.1038/nature09626;
RA   Nazarian R., Shi H.-B., Wang Q., Kong X.-J., Koya R.C., Lee H.,
RA   Chen Z.-G., Lee M.-K., Attar N., Sazegar H., Chodon T., Nelson S.F.,
RA   McArthur G.A., Sosman J.A., Ribas A., Lo R.S.;
RT   "Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or
RT   N-RAS upregulation.";
RL   Nature 468:973-977(2010).
//